New Zealand Study: Pfizer’s mRNA Vaccine Statistically Significant Link to Myocarditis

Join The Conversation! | https://trialsitenews.com/
Researchers from the New Zealand Ministry of Health as well as University of Auckland conducted a real-world observational study probing rates of adverse events of special interest (AESIs) associated with a primary dose of the Pfizer-BioNTech mRNA COVID-19 vaccine, BNT162b2, in the New Zealand population aged 5 years and up vaccinated from February 19, 2021, to February 10, 2022. Tapping into electronic health records, the Kiwi investigators looked for risk within the period of day 0 to 21 days after the jab compared with expected rates based on background health data from 2014 to 2019. Deriving an ‘incidence rate ratio " or "IRR " for each AESI, the study team estimated with 95% confidence intervals (CI), adjusting by age to calculate a risk difference and ultimately estimate the excess numbers of AESIs per 100,000 persons vaccinated.